Skip to content
Screener

Niagen Bioscience NAGE Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$31.1MBeat by $354.8K
EPS$0.04Beat by $0.02
Revenue estimate$30.8M
EPS estimate$0.02

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$34.4M
EPS estimate$0.01

Financials

Q2 2025

Income statement

See full
Revenue$31.1M+36.8%
Gross profit$20.2M+47.7%
Operating income$3.2M+1,344%
Net income$3.6M+24,160%
EPS (diluted)$0.04—

Balance sheet

See full
Cash & equivalents$60.5M+117%
Total debt$3.3M+5.4%
Total equity$64.2M+109%
Total assets$91.5M+69.4%

Cash flow

See full
Operating cash flow$1.3M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.11B—
Enterprise value$1.06B—
P/E62.8×—
P/S9.6×—

Profitability

See full
Gross margin63.6%+2.8pp
Operating margin14.3%+12.4pp
Net margin15.2%+13.8pp

Returns & leverage

See full
Return on equity37.4%+33.4pp
Debt / equity0.1×-0.1×
Current ratio3.9×+1.1×

Segments

By segment

See full
Consumer Products segment$22.7M+21.7%
Ingredients segment$7.6M+131%
Analytical Reference Standards and Services segment$799.0K+1.0%

FAQ

When did Niagen Bioscience report Q2 2025 earnings?
Niagen Bioscience (NAGE) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Niagen Bioscience's Q2 2025 revenue and EPS?
Niagen Bioscience reported revenue of $31.1M and eps of $0.04 for Q2 2025.
Did Niagen Bioscience beat estimates in Q2 2025?
Revenue beat the consensus estimate of $30.8M by $354.8K. EPS beat the consensus estimate of $0.02 by $0.02.
How did Niagen Bioscience's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 36.8% from $22.7M a year earlier.
Where can I find Niagen Bioscience's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001386570-25-000011) and the 10-Q periodic report (0001386570-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.